

Revolutionizing mRNA for Life

Pierre Kemula, Chief Financial Officer
SVB Leerink 10th Annual Global Healthcare Conference, February 2021

Forward-Looking Statements



The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation of CureVac N.V. (the “company”) contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

PIONEERS IN MEDICAL MRNA APPLICATIONS



- Founded in 2000
- Headquartered in Tübingen
- 511 employees*
- Nasdaq listed

UNIQUE MRNA TECHNOLOGY



- Unmodified mRNA
- Balanced immune activation
- Low dose activity

DEEP CLINICAL PIPELINE



- Prophylactic Vaccines
- Immuno-oncology
- Protein Therapies

MANUFACTURING EXPERTISE











- 3 GMP suites online
- 1 large-scale suite in progress
- Broad European CMO network
- Flexible and mobile GMP units

STRATEGIC PARTNERSHIPS




- Development support
- Medical affairs expertise
- Commercial execution power


Differentiated Technology Creates A New Class of Products

	FOCUS AREA	LEAD PROGRAM / COLLABORATION	FORMULATION
 Immune active applications	Prophylactic Vaccines <ul style="list-style-type: none"> Induction of antibody responses Induction of T-cell responses 	<ul style="list-style-type: none"> COVID-19 CVnCoV Rabies CV7202 	 Lipid nano-particle
	Oncology <ul style="list-style-type: none"> Induction of T-cell responses Induction of antibody responses Breaking of tolerance Activation of innate and adaptive immunity 	<ul style="list-style-type: none"> Tumor-associated antigens Shared neo-antigens CV8102 	 Lipid nano-particle  Peptide based
 Immune silent applications	Protein Therapy <ul style="list-style-type: none"> Oncology <ul style="list-style-type: none"> Use of the liver as a bioreactor Convey controlled immunogenicity Rare Diseases <ul style="list-style-type: none"> Ocular administration Mucosal delivery Other 	<ul style="list-style-type: none"> Genmab collaboration Harvard collaboration Yale collaboration CRISPR collaboration 	 Lipid nano-particle  Polymer based  Lipid nano-particle

CureVac Pipeline: A Diversified Portfolio




Unmodified mRNA: Differentiated Mode of Action, Mimics Natural Immunity



- Optimizing untranslated regions based on potent, tissue-specific regulatory elements
- Optimizations allow for increased translation efficiency and immunogenicity
- Maximizing ribosome interaction for increased protein expression enables **low dose activity**

UNIQUE MECHANISM OF ACTION

- Unmodified, natural mRNA
- Inducing type I interferons
- Inducing B and T cell responses
- Activating innate immune system
- Inducing boostable memory responses



PROPHYLACTIC VACCINES

- Active at **low dose** in humans
- Enables **multivalent** vaccines
- Fast, **large-scale** GMP production
- Multiple product candidates

CANCER VACCINES & IMMUNO-MODULATION

- **Innate** and **adaptive** immune activation
- Key activation of **T cell responses**
- Demonstrated **breaking of tolerance**
- Multiple product candidates

2020 – Year of Corporate Transformation

COVID-19 PROGRAM

Rigorous pre-clinical candidate selection

Accelerated clinical development in Phase 1, 2, 3

Manufacturing optimization and scale-up



BUSINESS EVOLUTION

Growing talent base:
>500 employees

Management expertise expansion

Strategic partnership



FINANCIAL EXECUTION

CVAC | **Nasdaq** Listed

Strong cash position:
~\$1.61 billion*



Our Core Mandate 2021: Deliver a Safe and Effective COVID-19 Vaccine

Succeeding in the clinic

- Expect to provide first efficacy data in late Q1/early Q2 2021
- Expect to apply for regulatory approval in Q2 2021

Creating capacity

- 3 in-house GMP certified suites
- 4th large-scale suite in progress
- Trans-European CMO network

Delivering the vaccine

- Partners for key operational, developmental & commercial support
- Cross-border and cross-institution collaborations



Clinical Development of COVID-19 Vaccine Candidate, CVnCoV



Phase 1

Germany / Belgium



DOSE ESCALATION TRIAL

- 2-20µg, placebo controlled
- 280 participants, **fully recruited**
- Expected data update:
Q1 2021

Phase 2a

Peru / Panama



DOSE CONFIRMATION TRIAL

- 6µg / 12µg, placebo controlled
- 690 participants, **fully recruited**
- Expected first data:
Q1 2021

Phase 2b/3


Europe / South America



SAFETY AND EFFICACY TRIAL

- 12µg, placebo controlled
- Exp. >37,000 participants, **recruiting**
- Expected interim data:
late Q1/early Q2 2021

Deliver on the Potential of the Curevac Technology to Create Sustainable Value



Collaboration and Services Agreement

Announced January 7, 2021

▪ Expertise and Infrastructure

Adding **operational knowledge**, broad **international reach** and regional access to support global supply of CureVac's CVnCoV

▪ Product Development Support

Adding muscle in areas such as **clinical operations, regulatory affairs, pharmacovigilance, and supply chain performance**

▪ Key Territory Operations

Adding country support for **EU member states and beyond**

CureVac to be Market Authorization Holder, option for Bayer in other markets outside the EU

Financials

▪ Service Agreement

▪ MAH:

▪ **CureVac** in the EU

▪ **Option for Bayer** in other geographies



World-Leading Vaccine Expertise with GSK for next-generation mRNA COVID-19 vaccines



Co-Development Partnership

Announced July 20, 2020, extended on February 3, 2021

■ Vaccine Development Expertise

Joint development of **2nd generation mRNA** vaccines including monovalent and multivalent approaches to address emerging variants in one vaccine

Joint efforts to address new and future variants to **stay one step ahead of the pandemic** with resources to research, development and manufacturing

Focus on developing **post-pandemic** vaccines

■ Commercialization Roles

GSK to be Marketing Authorization Holder with exclusive rights for development, manufacturing, and commercialization

CureVac to **retain three commercial areas**:
Germany, Austria, Switzerland

Financials

- Upfront: **€75 m**
- Milestone: **€75 m**
- Cost/profit split: **50:50**
- MAH: **GSK**



Research and Development Collaboration

Announced February 5, 2021

- **Scientific Variant Assessment and Selection**

Assessing novel **vaccines for SARS-CoV-2 variants** and vaccine approaches against selected mutations

Building on the VTF **leading scientific expertise**

Mitigate the effects of the **current pandemic**, help manage and prepare for **future outbreaks**

- **Clinical trial execution**

Clinical studies are **expected to be undertaken in the UK** towards securing marketing authorizations for jointly selected vaccines

- **Manufacturing and distribution**

Technology transfer by CureVac

Resulting vaccines expected to be **manufactured and distributed in the UK and its overseas and dependent territories**

Financials

- Each one carries **own R&D costs**
- **UK to purchase 50m doses**
- MAH: **CureVac**



World Class Variant
Vaccines Expert
Advisory Group



Department for
Business, Energy
& Industrial Strategy



Fast-track clinical
trial execution and
regulatory oversight




Variant
Surveillance

CVnCoV Shelf Life Allows for Established Cold-Chain Distribution


—5°C (41°F) SHELF LIFE OF AT LEAST 3 MONTHS*—

FOR 24 HOURS*



- Facilitated logistics for decentralized storage and large-scale vaccination efforts
- Expected positive impact on distribution, cost and waste compared to ultra-low cold chain requirements

Scaling-up Internal and External Manufacturing Capacities



RNA Printer™: Mobile Manufacturing Expected to Revolutionize GMP Process



Cloud based network
Rapid exchange of insights

GLOBAL HEALTH

PANDEMIC PREPAREDNESS in hospitals in outbreak regions

- Containing an outbreak directly at its origin

HEALTHCARE

CUSTOMIZED, POINT OF CARE mRNA therapeutics

- Expected to rapidly provide therapeutics tailored to patients' needs

RESEARCH


CLINICAL DEVELOPMENT ACCELERATION at lower costs

- Realizing different constructs and supplying studies onsite




Delivering up to 405 million doses of CVnCoV to European member states

- Agreement for 225m doses and an additional 180m dose option
- Upfront payment expected to mitigate project costs and help to de-risk production before regulatory approval
- Leveraging in-house manufacturing as well as integrated European manufacturing network



Our Financial Strength Enables the Company Transformation





**Thank you for your
interest**

CureVac
www.curevac.com